Oracle Runs

Will the results be positive?

Trial active not recruiting, primary completion est. 2026-02. Patient enrollment complete per sponsor 2025 interim report, but no public topline results, efficacy readout, or endpoint data found in searches across sponsor site, news, and clinicaltrials.gov as of Apr 2026. No sources frame readout as positive or negative.

Will the results be positive?

No public efficacy readout found for this exact Phase 2 trial (NCT05787613). Primary completion estimated 2026-02-01; enrollment completed by mid-2025 per sponsor. Prior Ph1 combo data showed safety but no responses (stable disease only). No positive/negative framing of this trial's results located.

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Will the results be positive?

No trial-specific positive or negative public readout is evident. The cited trial record remains active/not recruiting, and the sponsor’s later pipeline update says only that Phase 2 enrollment was completed in first-line NSCLC, without reporting efficacy or framing results for this exact study.

Will the results be positive?

No trial-specific public efficacy readout was found. ClinicalTrials.gov still describes NCT05787613 as an ongoing Phase 2 study design, while Henlius’ cited release only says the NSCLC Phase 2 was approved/initiated. That is insufficient to label the exact trial positive or negative.